AC
REVB icon

Armistice Capital’s Revelation Biosciences REVB Stock Holding History

Armistice Capital’s Portfolio REVB Stock Details REVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$388K Buy
323,241
+214,673
+198% +$415K 0.01% 181
2025
Q4 		$347K Buy
108,568
+88,568
+443% +$388K ﹤0.01% 236
2025
Q3 		$114K Buy
+20,000
New +$194K ﹤0.01% 319

Other funds holding REVB

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $3.65B AUM 41.88% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

Armistice Capital's REVB Position: Q1 2026 in Review

Armistice Capital increased its Revelation Biosciences (REVB) stake by 198% in Q1 2026, buying an estimated $415K and bringing the position to 323,241 shares worth $388K. The position accounts for 0.01% of the portfolio, ranked #181.

Armistice Capital first reported a position in REVB in Q3 2025 and has held it in 3 quarters since. 12 funds tracked by Wall St. Rank hold REVB as of Q1 2026.

  • Armistice Capital held 323,241 shares of Revelation Biosciences worth $388K as of Q1 2026.
  • Armistice Capital bought 214,673 Revelation Biosciences shares in Q1 2026, an estimated $415K.
  • Revelation Biosciences made up 0.01% of Armistice Capital's portfolio in Q1 2026, its #181 holding.
  • Armistice Capital first reported a position in Revelation Biosciences in Q3 2025 and has held it in 3 quarters since.
  • 12 funds tracked by Wall St. Rank held Revelation Biosciences as of Q1 2026.

Based on Armistice Capital's 13F filing for Q1 2026, filed 15 May 2026.